デジタルバイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、臨床業務別、治療領域別、最終用途別、地域別、セグメント別予測、2024年～2030年

デジタルバイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のデジタルバイオマーカー市場規模は2030年までに139億7,000万米ドルに達し、2024年から2030年までのCAGRは22.7％で成長すると予測されています。

この成長の背景には、ヘルスケア関連のモバイルアプリケーション＆デバイスの採用が増加していること、幅広い治療用途に関する認識が高まっていること、スマートフォンの利用が増加していること、斬新なウェアラブル技術が導入されていることなどがあります。2021年のアクセンチュア・ヘルス・アンド・ライフサイエンス・エクスペリエンス調査によると、米国に住む人々の26％が、ヘルスケア・アプリケーションやデバイスの導入により、ヘルスケア・サービスへのアクセス向上を経験しています。

さらに、政府機関は、COVID-19の発生によってもたらされた大きな苦難のため、デジタルバイオマーカーに基づく投薬の作成に関心を示しています。例えば、2022年3月、アストラゼネカは英国を拠点とする医療技術企業Huma Therapeuticsと提携し、さまざまな治療疾患向けのSoftware as a Medical Device（SaMD）コンパニオン・アプリケーションを開発しました。これらのアプリケーションは、予測アルゴリズム、デジタルバイオマーカー、実世界のデータを組み合わせたものです。

医薬品調査にかかるコストの上昇と、相対的な成功率の低さが、デジタルバイオマーカー（DBM）の急速な創出を後押ししています。この分野のDBMは、早期発症アルツハイマー病や認知症など、特定の分散型臨床研究分野に集中することを支援し、それによって医薬品開発の時間、失敗率、コストを下げます。healthxlというデジタル・ソリューション企業のブログ記事によると、デジタル医学協会（DiME）は最近、イーライリリー、メルク、バイオジェンなどのトップ製薬企業を集め、認知症やアルツハイマー病に関する一連のコア標準デジタル・エンドポイントを確認しました。これは、ヒトを対象とした新しい治療法の有効性評価の問題を解決し、新しい治療法の研究開発に費やされる時間と費用を削減するために行われました。

世界中の地域政府は、啓発プログラムの実施やデジタルヘルス開発への投資を通じて、バイオマーカーの導入を支援しています。UC Davis School of Medicineが2022年に発表した記事によると、UC Davis Healthが実施したDigital Health Equity Programは連邦政府から170万米ドルの資金提供を受けた。この政府資金は、北カリフォルニアとサクラメントに住む社会的弱者の医療機関へのアクセスを向上させることができる地域デジタル・パブリック・ヘルス・プラットフォームの開発に貢献すると期待されています。

AliveCor Inc.、Empatica, Inc.、Huma、VivoSenseなどの新興企業は、買収、提携、パートナーシップ、新製品の発売などの戦略を採用しており、予測期間中の市場成長を促進すると予測されています。例えば、2023年1月、デジタルヘルス企業であるHuma社は、デジタル臨床試験領域における能力を拡大するためにAlcedis社の買収を発表しました。この買収の目的は、開発プロセスのさまざまな段階にわたってヘルスケアソリューションを開発することです。

デジタルバイオマーカー市場レポートハイライト

• タイプ別では、ヘルスケア目的の新しいウェアラブルの出現により、ウェアラブルが2023年に39.5%の最大市場シェアを占めました。政府当局が新しいウェアラブルデバイスを承認しているため、新しいウェアラブルデバイスの市場需要が増加すると予測されます。
• 臨床診療に基づくと、診断デジタルバイオマーカーが2023年に32.4％の最大市場シェアを占めました。診断デジタルバイオマーカーは、ウェアラブル、モバイルアプリ、医療機器などのデジタル技術から得られる、健康状態や疾患の定量可能な指標です。生理学的データ、行動学的データ、生化学的データ、画像データ、患者報告データを分析することで、早期発見、正確な診断、個別化治療を可能にします。これらの革新的なツールは、患者の転帰を改善し、遠隔モニタリングや疾病管理を容易にすることで、ヘルスケアの進歩に貢献しています。
• 治療分野別では、治療用途の増加や世界の心血管障害の増加により、心血管疾患分野が2023年に19.8%のシェアを占めて市場を独占しました。
• 最終用途別では、ヘルスケア企業が2023年に50.1%の最大市場シェアを占めました。これは、ヘルスケア企業が臨床ケアと調査範囲にわたってデジタル測定の統合に取り組んでいるためです。
• 北米が市場を独占し、2023年に58.4％の収益シェアを占めました。これは、主要市場プレイヤーの強力なプレゼンス、重要な製品の発売、R&Dバイオマーカーへの投資の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 デジタルバイオマーカー市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助的な市場見通し。
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• デジタルバイオマーカー市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 デジタルバイオマーカー市場：タイプ別推定・動向分析

• タイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界のデジタルバイオマーカー市場のタイプ別展望
• 市場規模と予測および動向分析、2018年～2030年

第5章 デジタルバイオマーカー市場：臨床業務別推定・動向分析

• 臨床業務別市場シェア、2023年および2030年
• セグメントダッシュボード
• 世界のデジタルバイオマーカー市場の臨床業務別の展望
• 市場規模と予測および動向分析、2018年～2030年

第6章 デジタルバイオマーカー市場：治療領域別推定・動向分析

• 治療領域別市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界のデジタルバイオマーカー市場の治療領域別展望
• 市場規模と予測および動向分析、2018年～2030年

第7章 デジタルバイオマーカー市場：エンドユーザー別推定・動向分析

• エンドユーザータイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界のデジタルバイオマーカー市場エンドユーザー別展望
• 市場規模と予測および動向分析、2018年～2030年

第8章 デジタルバイオマーカー市場：地域別推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域別市場ダッシュボード
• 世界の地域別市場スナップショット
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 北米： SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州：SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋：SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ： SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Company Market Position Analysis, 2023
  • ActiGraph LLC
  • AliveCor Inc.
  • Koneksa
  • Altoida Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Empatica Inc.
  • Vivo Sense
  • IXICO plc
  • Adherium Limited
  • Vivo Sense
  • Neurotrack Technologies, Inc.
  • Aural Analytic
  • Huma Therapeutics
  • Sonde Health, Inc.
  • Clario
  • Imagene AI
  • Brainomix
  • Kinsa Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 North America digital biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 4 North America digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 5 North America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 6 North America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 7 North America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 8 U.S digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 9 U.S digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 10 U.S digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 11 U.S digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Canada digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 13 Canada digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 14 Canada digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 15 Canada digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 13 Mexico digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 14 Mexico digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 15 Mexico digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 16 Europe digital biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 17 Europe digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 18 Europe digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 19 Europe digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 20 Europe digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 21 U.K digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 22 U.K digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 23 U.K digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 24 U.K digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 21 France digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 22 France digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 23 France digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 24 France digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Germany digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 26 Germany digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 27 Germany digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 28 Germany digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 29 Denmark digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 30 Denmark digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 31 Denmark digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 32 Denmark digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 33 Italy digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 34 Italy digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 35 Italy digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 36 Italy digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Sweden digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 38 Sweden digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 39 Sweden digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 40 Sweden digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific digital biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 46 China digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 47 China digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 48 China digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 49 China digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 50 Japan digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 51 Japan digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 52 Japan digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 53 Japan digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 54 India digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 55 India digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 56 India digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 57 India digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 58 Australia digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 59 Australia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 60 Australia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 61 Australia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 62 South Korea digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 63 South Korea digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 64 South Korea digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 65 South Korea digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 66 Latin America digital biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 67 Latin America digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 68 Latin America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 69 Latin America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 70 Latin America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 71 Brazil digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 72 Brazil digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 73 Brazil digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 74 Brazil digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 71 Argentina digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 72 Argentina digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 73 Argentina digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 74 Argentina digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 79 MEA digital biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 80 MEA digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 81 MEA digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 82 MEA digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 83 MEA digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 84 South Africa digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 85 South Africa digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 86 South Africa digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 87 South Africa digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia digital biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 89 UAE digital biomarker market, by type, 2018 - 2030 (USD Million)
• Table 90 UAE digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
• Table 91 UAE digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 92 UAE digital biomarker market, by end user, 2018 - 2030 (USD Million)
• Table 93 Kuwait digital biomarker market, by type, 2018 - 2030 (USD Million)
• Table 94 Kuwait digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
• Table 95 Kuwait digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 96 Kuwait digital biomarker market, by end user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Digital Biomarker: market outlook
• Fig. 9 Digital Biomarker competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook.
• Fig. 12 Digital Biomarker driver impact
• Fig. 13 Digital Biomarker restraint impact
• Fig. 14 Digital Biomarker strategic initiatives analysis
• Fig. 16 Digital Biomarkers Market: By Type Movement Analysis
• Fig. 17 Wearable market estimates and forecasts, 2018 - 2030
• Fig. 18 Mobile based applications market estimates and forecasts, 2018 - 2030
• Fig. 19 Sensors market estimates and forecasts, 2018 - 2030
• Fig. 20 Others market estimates and forecasts, 2018 - 2030
• Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis
• Fig. 22 Diagnostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Monitoring digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Predictive and prognostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Others digital biomarker market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis
• Fig. 27 Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Psychiatric disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Sleep & movement disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis
• Fig. 35 Healthcare companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Healthcare providers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 Regional outlook, 2023 & 2030
• Fig. 41 North America digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 42 U.S. digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 43 Canada digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 43 Mexico digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 44 Europe digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 45 U.K. digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 45 France digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 46 Germany digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 45 Spain digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 47 Denmark digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 47 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 47 Norway digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 48 Italy digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 49 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 50 Asia Pacific digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 51 Japan digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 52 China digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 53 India digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 54 South Korea digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 55 Australia digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 56 Latin America digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 57 Brazil digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 58 Argentina digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 59 MEA digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 60 South Africa digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 61 Saudi Arabia digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 62 UAE digital biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 63 Kuwait digital biomarkers market estimates and forecasts, 2018 - 2030

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer's or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer's disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights:

• Based on type, wearables held the largest market share of 39.5% in 2023, owing to the emergence of new wearables for healthcare purposes. It is anticipated that the market demand for new wearable devices is expected to increase because of government authorities approving new wearable devices
• Based on clinical practice, the diagnosis digital biomarkers held the largest market share of 32.4% in 2023. Diagnosis digital biomarkers are quantifiable indicators of health conditions or diseases, derived from digital technologies such as wearables, mobile apps, and medical devices. They enable early detection, accurate diagnosis, and personalized treatment by analyzing physiological, behavioral, biochemical, imaging, and patient-reported data. These innovative tools contribute to the advancement of healthcare by improving patient outcomes and facilitating remote monitoring and disease management
• Based on therapeutic area,the cardiovascular disease segment dominated the market with a share of 19.8% in 2023, owing to the growing number of therapeutic applications and increasing incidences of cardiovascular disorders globally
• Based on end use, the healthcare companies held the largest market share of 50.1% in 2023, owing to the fact that healthcare companies have been working toward integrating digital measurements across the spectrum of clinical care & research
• North America dominated the market and accounted for a revenue share of 58.4% in 2023, owing to the strong presence of leading market players, significant product launches, and an increase in investments in the R&D biomarkers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Clinical Practice
  • 1.2.3. Therapeutic Area
  • 1.2.4. End User
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Clinical practice outlook
  • 2.2.3. Therapeutic Area Outlook
  • 2.2.4. End User outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Digital Biomarker Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Digital Biomarker Market Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Wearable
    • 4.4.1.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Mobile based applications
    • 4.4.2.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Sensors
    • 4.4.3.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

• 5.1. Clinical Practice Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Digital Biomarker Market Clinical Practice Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Diagnostic digital biomarkers
    • 5.4.1.1. Diagnostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Monitoring digital biomarkers
    • 5.4.2.1. Monitoring digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Predictive and Prognostic digital biomarkers
    • 5.4.3.1. Predictive and Prognostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Others (Safety, Pharmacodynamics/ Response, Susceptibility)
    • 5.4.4.1. Others (Safety, Pharmacodynamics/ Response, Susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Therapeutic Area Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Digital Biomarker Market by Therapeutic Area Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Cardiovascular and metabolic disorders (CVMD)
    • 6.4.1.1. Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Respiratory diseases
    • 6.4.2.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Psychiatric disorders
    • 6.4.3.1. Psychiatric disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Sleep & movement disease
    • 6.4.4.1. Sleep & movement disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Neurological disorders
    • 6.4.5.1. Neurological disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Musculoskeletal disorders
    • 6.4.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Others (Diabetes, Pain Management)
    • 6.4.7.1. Others (Diabetes, Pain Management) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

• 7.1. End User Type Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Digital Biomarker Market by End User Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Healthcare companies
    • 7.4.1.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Healthcare Providers
    • 7.4.2.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Healthcare Providers
    • 7.4.3.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Others (Patient, caregivers)
    • 7.4.4.1. Others (Patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Company Market Position Analysis, 2023
  • 9.3.2. ActiGraph LLC
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. AliveCor Inc.
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Koneksa
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Altoida Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Amgen Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Biogen Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Empatica Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Vivo Sense
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. IXICO plc
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Adherium Limited
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Vivo Sense
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Neurotrack Technologies, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Aural Analytic
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Huma Therapeutics
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Sonde Health, Inc.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Clario
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. Imagene AI
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Product benchmarking
    • 9.3.18.4. Strategic initiatives
  • 9.3.19. Brainomix
    • 9.3.19.1. Company overview
    • 9.3.19.2. Financial performance
    • 9.3.19.3. Product benchmarking
    • 9.3.19.4. Strategic initiatives
  • 9.3.20. Kinsa Inc.
    • 9.3.20.1. Company overview
    • 9.3.20.2. Financial performance
    • 9.3.20.3. Product benchmarking
    • 9.3.20.4. Strategic initiatives